Christine Waibel

Kantonsspital Baden — Switzerland

Medicine · Health Sciences

8h-index511citations22works1.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(9), Cancer Immunotherapy and Biomarkers(7), Lung Cancer Diagnosis and Treatment(6), Occupational and environmental lung diseases(5), Pleural and Pulmonary Diseases(5)

Publications22 total

EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
Journal of Thoracic Oncology·2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Nature Communications·2025Open Access
2970P SLFN11 expression as potential prognostic marker in pleural mesothelioma
Annals of Oncology·2025
242P: SAKK 17/18 ORIGIN trial: Efficacy and safety from a multicentre phase II trial of gemcitabine and atezolizumab in pretreated patients with pleural mesothelioma
Journal of Thoracic Oncology·2025Open Access
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
JTO Clinical and Research Reports·2024· 4 citedOpen Access
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
JTO Clinical and Research Reports·2024· 5 citedOpen Access
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2024Open Access
Sweet syndrome with peripheral neuropathy in a patient with metastatic clear cell renal cell carcinoma
BMJ Case Reports·2024
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Lung Cancer·2023· 13 cited
1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Annals of Oncology·2023· 1 citedOpen Access
2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Annals of Oncology·2023· 2 citedOpen Access
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
Journal of Clinical Oncology·2023· 9 cited
1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)
Annals of Oncology·2022· 6 citedOpen Access
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study
Lung Cancer·2022· 17 citedOpen Access
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
Journal of Clinical Oncology·2021· 336 citedOpen Access
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial
SSRN Electronic Journal·2021Open Access
1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Annals of Oncology·2020· 12 citedOpen Access
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
Journal of Clinical Oncology·2020· 39 cited
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Annals of Oncology·2020· 32 citedOpen Access
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial
Annals of Oncology·2019· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Michael Mark(17), Sacha I. Rothschild(14), Laetitia Mauti(13), Christian Britschgi(13), Patrizia Froesch(13), Martin Früh(11), Adrienne Bettini(10), Miklos Pless(8), Markus Joerger(7), Wolf-Dieter Janthur(7), Nicolas Mach(7), Sabine Schmid(7), Alfred Zippelius(6), E.I. Eboulet(6), Solange Peters(6), Adrian F. Ochsenbein(6), Michel González(6), M. Frueh(6), Alfredo Addeo(6), Lisa Holer(6)